Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24978884 | 0.85 | CYP2C19 (0.41) | CYP3A4CYP2C19HPGDSMN1; SMN2LMNA | |
| SCHEMBL20069769 | 0.74 | RET (0.36) | CYP2C19CCR1OPRM1OPRL1 | |
| SCHEMBL18377458 | 0.71 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL20147940 | 0.69 | TRPA1 (0.37) | CCR1OPRM1OPRL1 | |
| SCHEMBL20581620 | 0.69 | CYP2C19 (0.36) | CYP3A4CYP2C19HPGDCYP2C9OPRM1 | |
| SCHEMBL22857028 | 0.68 | KDM4E (0.38) | SMN1; SMN2CCR1OPRM1 | |
| SCHEMBL22348421 | 0.68 | CHRM1 (0.37) | CYP2C19HPGDNPSR1ALDH1A1 | |
| SCHEMBL22347199 | 0.68 | CHRM1 (0.37) | CYP2C19HPGDNPSR1ALDH1A1 | |
| SCHEMBL10081019 | 0.67 | — | — | |
| SCHEMBL941571 | 0.65 | EPHX1 (0.43) | CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381112-A1 | Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ | VACCITECH NORTH AMERICA, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230026627-A1 | Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery | VACCITECH NORTH AMERICA, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026627-A1 | Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery | TNFSF10, SELPLG, FCGRT | CYP3A4 848/4885CYP2C19 1188/4885HPGD 4511/4885 |
| US-20230381112-A1 | Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ | SBDS, MTDH, DLST | CYP3A4 1359/4885CYP2C19 2894/4885HPGD 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.